Sana Biotechnology Management
Management criteria checks 3/4
Sana Biotechnology's CEO is Steve Harr, appointed in Sep 2018, has a tenure of 6.25 years. total yearly compensation is $2.67M, comprised of 24.7% salary and 75.3% bonuses, including company stock and options. directly owns 3.97% of the company’s shares, worth $15.50M. The average tenure of the management team and the board of directors is 0.9 years and 5.4 years respectively.
Key information
Steve Harr
Chief executive officer
US$2.7m
Total compensation
CEO salary percentage | 24.7% |
CEO tenure | 6.3yrs |
CEO ownership | 4.0% |
Management average tenure | less than a year |
Board average tenure | 5.4yrs |
Recent management updates
Recent updates
Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus
Dec 04Sana Biotechnology: The Story Becomes Murkier
Nov 19We Think Sana Biotechnology (NASDAQ:SANA) Needs To Drive Business Growth Carefully
Nov 01Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline
Jul 14We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Jul 12Sana Biotechnology: Now In Overbought Territory
Mar 17Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)
Jan 11Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
Dec 30Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 14Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?
May 26We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate
Dec 19Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation
Sep 03Sana Biotechnology A Buy For Potential Cancer Therapies
Jun 27Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?
May 16Sana Biotechnology: Exciting Preclinical Science
Feb 12Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?
Oct 13Sana Biotechnology: Hypoimmune Cell Therapies
Jul 01Sana Biotechnology reports Q1 results
May 05CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$306m |
Jun 30 2024 | n/a | n/a | -US$245m |
Mar 31 2024 | n/a | n/a | -US$309m |
Dec 31 2023 | US$3m | US$659k | -US$283m |
Sep 30 2023 | n/a | n/a | -US$276m |
Jun 30 2023 | n/a | n/a | -US$362m |
Mar 31 2023 | n/a | n/a | -US$320m |
Dec 31 2022 | US$4m | US$645k | -US$269m |
Sep 30 2022 | n/a | n/a | -US$300m |
Jun 30 2022 | n/a | n/a | -US$298m |
Mar 31 2022 | n/a | n/a | -US$207m |
Dec 31 2021 | US$1m | US$611k | -US$356m |
Sep 30 2021 | n/a | n/a | -US$358m |
Jun 30 2021 | n/a | n/a | -US$327m |
Mar 31 2021 | n/a | n/a | -US$433m |
Dec 31 2020 | US$7m | US$535k | -US$285m |
Compensation vs Market: Steve's total compensation ($USD2.67M) is about average for companies of similar size in the US market ($USD2.15M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
CEO
Steve Harr (54 yo)
6.3yrs
Tenure
US$2,671,662
Compensation
Dr. Steven D. Harr, also known as Steve, M.D., is President and Chief Executive Officer at Sana Biotechnology, Inc. since September 2018 and also serves as its Director since October 2018. He served as the...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 6.3yrs | US$2.67m | 3.97% $ 15.5m | |
Acting CFO | less than a year | no data | 0.066% $ 258.1k | |
Senior VP & Chief Technical Officer | less than a year | no data | no data | |
Executive VP & Chief Scientific Officer | less than a year | no data | no data | |
Executive VP | 2.3yrs | US$4.26m | 0.042% $ 162.4k | |
Senior VP & Head of Hypoimmune Platform | 5.8yrs | no data | no data | |
Chief Medical Officer | 1.7yrs | no data | no data | |
Head of Intellectual Property | less than a year | no data | no data | |
Head of Oncology Research & Development | less than a year | no data | no data |
0.9yrs
Average Tenure
54yo
Average Age
Experienced Management: SANA's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 6.2yrs | US$2.67m | 3.97% $ 15.5m | |
Independent Director | 6.2yrs | US$294.80k | 0.0062% $ 24.2k | |
Independent Director | 4.6yrs | US$314.80k | 0.0032% $ 12.4k | |
Independent Director | 4.7yrs | US$302.30k | 0.091% $ 354.1k | |
Independent Director | 6.2yrs | US$299.80k | 0.067% $ 261.2k | |
Independent Director | 4.1yrs | US$314.80k | 0% $ 0 | |
Vice Chairman | 6.1yrs | no data | 1.21% $ 4.7m | |
Independent Chairman of the Board | 6.2yrs | US$354.80k | 2.59% $ 10.1m | |
Independent Director | 4yrs | US$299.80k | 0.0090% $ 35.0k | |
Independent Director | 4yrs | US$302.30k | 0% $ 0 |
5.4yrs
Average Tenure
62.5yo
Average Age
Experienced Board: SANA's board of directors are considered experienced (5.4 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/26 01:40 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sana Biotechnology, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Geoffrey Meacham | BofA Global Research |
Alec Stranahan | BofA Global Research |
Samantha Lynn Semenkow | Citigroup Inc |